NeuroCentury Paweł Świeboda

It is the time of big promise in the diagnosis and treatment of Alzheimer’s Disease (AD). There are dozens of genetic risks discovered in recent years. There are also emerging blood tests whose performance in diverse groups of patients is currently being confirmed. New disease-modifying drugs help to remove beta-amyloid plaques from the brain. While AD is a complex disease and its onset is connected to multiple biochemical pathways in cells, the new treatments target a core component of Alzheimer’s Disease. 

 

In this episode of NeuroCentury, its host Paweł Świeboda talks to Professor Stephen Salloway, one of the leading scholars working on biomarkers and drug development for prevention and early treatment of Alzheimer’s Disease. He is Professor of Psychiatry and Human Behaviour and Professor of Neurology at Brown University. He is also Founding Director of the Memory and Ageing Program at Butler Hospital.

 

The conversation helps to disentangle what the new era in diagnosis and treatment of AD can bring, with the advent of monoclonal antibodies and the emergence of new generation brain health services. Rethinking the care journey is part of the process, since treatments need to start before symptoms emerge, or possibly even before the amyloid build-up. Future discovery research will go beyond lowering of amyloid levels to have an even bigger impact on the disease.



#neurocentury #AD #Alzheimer’sDisease #brain #brainhealth

______________

neurocentury.com



Music for the NeuroCentury podcast is composed by Rafał Kulczycki

Ascent of AI in healthcare opens the way to precision and personalized medicine becoming a standard of care in neurology. One important aspect is extracting more meaningful data from brain imaging and scans, given how crucial they are for the diagnosis and monitoring in neurology. Facing rising demand for brain MRI procedures, radiologists can increasingly have their AI companions, helping them to manage the task, as clinical burdens and disease complexity continue to increase.

In the episode of NeuroCentury, its host Paweł Świeboda discusses these game-changing developments with Wim Van Hecke, founder and CEO of Icometrix, a company that is enabling radiologists and physicians optimize their workflows and clinical decision-making Wim trained as engineer and specialized in biomedical engineering and neuroimaging. He is author or co-author of over 200 scientific publications and editor of a clinical neuroimaging handbook. He is also a visiting professor at Free University of Brussels.

Icometrix has developed a suite of tools for quantitative assessment of brain MRI scans in the different fields of neurology. It is now transforming the care of patients with neurological disorders. As disease-modifying treatments start to become available for Alzheimer’s disease, the importance of advanced diagnostic and prognostic technologies and biomarkers coming together to standardize care pathways, has never been greater.

#neurocentury #healthcare #brain #neurotechnology #neuroimaging #AI



________________

neurocentury.com



Music for the NeuroCentury podcast is composed by Rafał Kulczycki

What are the trends on the market for medical technologies and medical devices in the neuro space? How much of the impressive innovation coming out of the labs carries the promise of making impact on the lives of patients? In this episode of NeuroCentury, Paweł Świeboda talks to Enric Claverol-Tinturé, Programme Manager for Medical Technologies and Medical Devices at the European Innovation Council, the EU’s prime vehicle for funding breakthrough innovation.

Enric is well versed in all matters neuro. He has a PhD degree in engineering and neuroscience and worked as scientist at the California Institute of Technology and the Barcelona-based Bioengineering Research Centre. He then run a spin-off company and founded a technology start-up. Enric’s ample experience in funding innovation includes his tenure as Director General of the Catalonia Foundation for R&I and the current pivotal role at the EIC.

Paweł and Enric discuss promising developments in neuro-electronics and neurotechnology more broadly. They reflect on how interdisciplinary collaboration can be further encouraged, so as to leverage advances in compact electronics, powerful computation and brain medicine. Enric explains what type of projects the EIC looks for and what entrepreneurial researchers as well as current and future founders should consider when preparing to apply for an EIC grant.

#neurocentury #neurotechnology #neuroscience



________________

neurocentury.com



Music for the NeuroCentury podcast is composed by Rafał Kulczycki

What is neuroethics and how it has evolved to make brain research and neurotechnology ethical in both medical and non-medical applications. In the latest episode of NeuroCentury, Paweł Świeboda explores these questions with Dr Arleen Salles, Founding Board Member of the Institute of Neuroethics in Atlanta, Georgia and Director of Neuroética in Buenos Aires, Argentina. Arleen co-led the work on Responsible Research and Innovation in the Human Brain Project (2014-2023) and serves as an Executive Board Member of the International Neuroethics Society.

Paweł and Arleen discuss methods of integrating ethical and social considerations into neuroscience and neurotechnology projects: why are the questions about autonomy, integrity, agency or identity so important and how they should be addressed in the research and innovation process early on. The conversation considers whether self-regulation can successfully lead companies to incorporate ethics into their business models. Paweł and Arleen also explore the meaning of consent, one of the basic principles in biomedical ethics, in neuro-related research. Their discussion raises the question whether the debate over responsible AI design, development and deployment should be conducted jointly with the one on social and ethical considerations in neurotechnology.

In addition, the conversation is about international efforts on responsible innovation in neurotechnology, starting with the OECD Recommendation in 2019, the work of UN bodies, and more recently, the European Union. It also considers what role cultural considerations need to play in the debate over neurotechnology governance. 

 #neurocentury #neuroethics #neurotechnology #brain



_______________

neurocentury.com



Music for the NeuroCentury podcast is composed by Rafał Kulczycki

A new generation of robots is emerging, directly inspired by the intelligence and bodies of living organisms. What will result is a symbiosis of the human and the robot, says Prof. Dario Floreano, Director of the Laboratory of Intelligent Systems at the EPFL in Lausanne, in this episode of NeuroCentury, recorded at the Dubai Future Forum 2023.  

Dario Floreano led the National Competence Centre in Research for Robotics in Switzerland, 2010-2022, a large consortium of academic and research institutions specializing in different aspects of robotic technology. He is co-author of the book “Tales from a Robotic World”, together with Nicola Nosengo.

The conversation covers programmes to develop intelligent robots for restoring, preserving and assisting humans. Wearable robotics is the type of robotics where the robot perceives what the person does and acts on the person by supporting his/her actions. Dario takes us through developments which started from large, bulky robots for neurorehabilitation, to wearable ones, and onto the situation in which the robot disappears and becomes embedded, integrated in the human.

Paweł and Dario discuss educational robotics and how 80 thousand robots are now deployed in Swiss schools and elsewhere for teaching and learning. They explore the impact of the rise of robotics on the labour market, given the ongoing automation of many human tasks. Looking into the future, Paweł asks Dario about biohybrid robots, ones that weave electronics with living cells.

#neurocentury #robots #roboticworld #neurotechnology

________________

neurocentury.com



Music for the NeuroCentury podcast is composed by Rafał Kulczycki

Coming from Dubai, this episode of NeuroCentury, is devoted to advances in genetics and their impact on the treatment of brain disorders. Paweł Świeboda talks to Mohammed Uddin, a human geneticist with a focus on the genetics neurological and neuropsychiatric disorders. Mohammed is Professor at the University of Medicine and Health Sciences in Dubai, an important emerging hub for genomic medicine.

Entire buckets of genes are now established in genome-wide discovery studies. Yet, the pathway towards understanding the underlying biology is not always obvious. Many genes might be plausible candidates for associated variants. Most traits are polygenic, and many genetic variants have small effect. In this context, the episode covers the future of clinical genomics, with emphasis on mass scale modelling to characterize variants of uncertain significance, the use of Machine Learning in variant detection, single cell sequencing and the Pangenome initiative to identify population-specific risk factors

The conversation zooms in on Autism Spectrum Disorder, a neurodevelopmental disorder affecting 1 in 44 children globally. Over 100 genes have been identified to be strongly associated with the ASD. Mohammed’s work has shown that non-neuronal cells, the astrocytes, play a strong role in the development of autism.

Mohammed has recently launched a startup GenomeArc with a platform for ultrafast genome variant classification and interpretation. In the conversation, he explains why it is so important to obtain this type of rapid reading of the genome.

 #neurocentury #genetics #genomicmedicine #brainhealth



_______________

neurocentury.com



Music for the NeuroCentury podcast is composed by Rafał Kulczycki